Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06923124 · ClinicalTrials.gov registry record

A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life

A clinical trial of Familial Mediterranean Fever, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
44
Enrollment target
1
Study location

NCT06923124 is a study of Familial Mediterranean Fever that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 44 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06923124, a study of Familial Mediterranean Fever, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
44 participants
Enrollment target
1
Study location

Study Summary

A retrospective, non-interventional, single-center study conducted in Spain, based on the collection of data from the medical histories of patients with Familial Mediterranean fever (FMF) diagnosed during childhood from January 2005 to December 2021. Data from the patients' medical records was collected retrospectively, from the time of diagnosis to the current moment of the patient's enrollment in the study. Patients had a minimum follow-up of 3 months after diagnosis.

Study Locations (1)

New Jersey

  • Novartis - East Hanover

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2023-03-30
Est. Completion 2024-05-28

Sponsor

Novartis Pharmaceuticals

1,375 total trials

What the Registry Record Tells You About NCT06923124

The ClinicalTrials.gov registry entry for NCT06923124 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Familial Mediterranean Fever appearing as the primary indexed condition, and to 0 interventions.

NCT06923124 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT06923124 about?

NCT06923124 is a clinical study titled "A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life". A retrospective, non-interventional, single-center study conducted in Spain, based on the collection of data from the medical histories of patients with Familial Mediterranean fever (FMF) diagnosed during childhood from January 2005 to December 2021. Data from the patients' medical records was coll...

What is the current status of trial NCT06923124?

This trial is currently completed. The enrollment target is 44 participants. The study started on 2023-03-30. Estimated completion is 2024-05-28.

What conditions does trial NCT06923124 study?

This clinical trial studies the following conditions: Familial Mediterranean Fever.

Who is sponsoring clinical trial NCT06923124?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06923124 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Familial Mediterranean Fever

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.